{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:11:04Z","timestamp":1788379864183,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the healthcare business of Merck KGaA, Darmstadt, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Tepotinib is a highly selective, potent, mesenchymal-epithelial transition factor (MET) inhibitor, approved for the treatment of non-small cell lung cancer harboring <jats:italic>MET<\/jats:italic> exon 14 skipping alterations. The aims of this work were to investigate the potential for drug-drug interactions via cytochrome P450 (CYP) 3A4\/5 or P-glycoprotein (P-gp) inhibition. In vitro studies were conducted in human liver microsomes, human hepatocyte cultures and Caco-2 cell monolayers to investigate whether tepotinib or its major metabolite (MSC2571109A) inhibited or induced CYP3A4\/5 or inhibited P-gp. Two clinical studies were conducted to investigate the effect of multiple dose tepotinib (500\u00a0mg once daily orally) on the single dose pharmacokinetics of a sensitive CYP3A4 substrate (midazolam 7.5\u00a0mg orally) and a P-gp substrate (dabigatran etexilate 75\u00a0mg orally) in healthy participants. Tepotinib and MSC2571109A showed little evidence of direct or time-dependent CYP3A4\/5 inhibition (IC<jats:sub>50<\/jats:sub>\u2009&gt;\u200915\u00a0\u03bcM) in vitro, although MSC2571109A did show mechanism-based CYP3A4\/5 inhibition. Tepotinib did not induce CYP3A4\/5 activity in vitro, although both tepotinib and MSC2571109A increased CYP3A4 mRNA. In clinical studies, tepotinib had no effect on the pharmacokinetics of midazolam or its metabolite 1\u2019-hydroxymidazolam. Tepotinib increased dabigatran maximum concentration and area under the curve extrapolated to infinity by 38% and 51%, respectively. These changes were not considered to be clinically relevant. Tepotinib was considered safe and well tolerated in both studies. The potential of tepotinib to cause clinically relevant DDI with CYP3A4- or P-gp-dependent drugs at the clinical dose is considered low. Study 1 (midazolam): NCT03628339 (registered 14 August 2018). Study 2 (dabigatran): NCT03492437 (registered 10 April 2018).<\/jats:p>","DOI":"10.1007\/s10637-023-01378-z","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T19:01:47Z","timestamp":1688670107000},"page":"596-605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates"],"prefix":"10.1007","volume":"41","author":[{"given":"\u00d6zkan","family":"Yalkinoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Krebs-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"L\u00fcpfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Heuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herlind","family":"Biedert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrim","family":"Bytyqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Strotmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"1378_CR1","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1158\/1078-0432.ccr-12-3247","volume":"19","author":"F Bladt","year":"2013","unstructured":"Bladt F, Faden B, Friese-Hamim M et al (2013) EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin Cancer Res 19:2941\u20132951. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-3247","journal-title":"Clin Cancer Res"},{"key":"1378_CR2","unstructured":"US Food and Drug Administration (2021) TEPMETKO (tepotinib) Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214096s000lbl.pdf. Accessed 4 Feb 2022"},{"key":"1378_CR3","unstructured":"Anvisa (2021) Tepotinib approval (Brazil). https:\/\/www.gov.br\/anvisa\/pt-br\/composicao\/diretoria-colegiada\/reunioes-da-diretoria\/votos\/2020\/rop-13.2020\/item-2-4-3-voto-161-dire4.pdf\/view. Accessed 27 Jul 2021"},{"key":"1378_CR4","unstructured":"Government of Canada (2021) Qualifying Notice for Tepmetko. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/notice-compliance\/conditions\/qualifying-notice-tepmetko-242300.html. Accessed 27 Jul 2021"},{"key":"1378_CR5","unstructured":"SwissMedic (2021) TEPMETKO approval (Switzerland). https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/new-medicines\/tepmetko-filmtabletten-tepotinibum.html. Accessed 27 Jul 2021"},{"key":"1378_CR6","unstructured":"PMDA (2020) TEPMETKO approval (Japan). https:\/\/www.pmda.go.jp\/files\/000236338.pdf. Accessed 27 Jul 2021"},{"key":"1378_CR7","doi-asserted-by":"publisher","unstructured":"Hanna NH, Robinson AG, Temin S et al (2021) Therapy for stage IV non\u2013small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol 39:1040\u20131091 [Erratum: J Clin Oncol 2021;39(22):2520]. https:\/\/doi.org\/10.1200\/JCO.20.03570","DOI":"10.1200\/JCO.20.03570"},{"key":"1378_CR8","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Non-Small Cell Lung Cancer V3.2022. \u00a9 National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed 10 May 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way"},{"key":"1378_CR9","unstructured":"Japanese Lung Cancer Society (2020) Lung Cancer Practice Guidelines. https:\/\/www.haigan.gr.jp. Accessed 13 May 2021"},{"key":"1378_CR10","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3390\/cancers6031736","volume":"6","author":"F Bladt","year":"2014","unstructured":"Bladt F, Friese-Hamim M, Ihling C et al (2014) The c-Met inhibitor MSC2156119J effectively inhibits tumor growth in liver cancer models. Cancers (Basel) 6:1736\u20131752. https:\/\/doi.org\/10.3390\/cancers6031736","journal-title":"Cancers (Basel)"},{"key":"1378_CR11","first-page":"962","volume":"7","author":"M Friese-Hamim","year":"2017","unstructured":"Friese-Hamim M, Bladt F, Locatelli G et al (2017) The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. Am J Cancer Res 7:962\u2013972","journal-title":"Am J Cancer Res"},{"key":"1378_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","volume":"28","author":"X Le","year":"2022","unstructured":"Le X, Sakai H, Felip E et al (2022) Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: Outcomes in patient subgroups from the VISION study with relevance for clinical practice. Clin Cancer Res 28:1117\u20131126. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2733","journal-title":"Clin Cancer Res"},{"key":"1378_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/psp4.12602","volume":"10","author":"W Xiong","year":"2021","unstructured":"Xiong W, Friese-Hamim M, Johne A et al (2021) Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose. CPT Pharmacometrics Syst Pharmacol 10:428\u2013440. https:\/\/doi.org\/10.1002\/psp4.12602","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1378_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.6004\/jadpro.2013.4.4.7","volume":"4","author":"PharmD McDonnell","year":"2013","unstructured":"McDonnell PharmD, BCOP AM, Dang, PharmD, BCPS CH, (2013) Basic Review of the Cytochrome P450 System. J Adv Pract Oncol 4:263\u2013268. https:\/\/doi.org\/10.6004\/jadpro.2013.4.4.7","journal-title":"J Adv Pract Oncol"},{"key":"1378_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103\u2013141. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007","journal-title":"Pharmacol Ther"},{"key":"1378_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fonc.2014.00041","volume":"4","author":"FJ Sharom","year":"2014","unstructured":"Sharom FJ (2014) Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: Its role in modulating protein function. Front Oncol 4:41. https:\/\/doi.org\/10.3389\/fonc.2014.00041","journal-title":"Front Oncol"},{"key":"1378_CR17","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s10637-020-00926-1","volume":"38","author":"A Johne","year":"2020","unstructured":"Johne A, Scheible H, Becker A et al (2020) Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers. Invest New Drugs 38:1507\u20131519. https:\/\/doi.org\/10.1007\/s10637-020-00926-1","journal-title":"Invest New Drugs"},{"key":"1378_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1124\/dmd.32.6.647","volume":"32","author":"RL Walsky","year":"2004","unstructured":"Walsky RL, Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647\u2013660. https:\/\/doi.org\/10.1124\/dmd.32.6.647","journal-title":"Drug Metab Dispos"},{"key":"1378_CR19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1023\/A:1010994022294","volume":"18","author":"GT Tucker","year":"2001","unstructured":"Tucker GT, Houston JB, Huang SM (2001) Optimizing drug development: Strategies to assess drug metabolism\/transporter interaction potential - Toward a consensus. Pharm Res 18:1071\u20131080. https:\/\/doi.org\/10.1023\/A:1010994022294","journal-title":"Pharm Res"},{"key":"1378_CR20","unstructured":"US Food and Drug Administration (2020) In Vitro Drug Interaction Studies \u2014 Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions"},{"key":"1378_CR21","first-page":"231","volume-title":"Drug-Drug Interactions","author":"BW Ogilvie","year":"2020","unstructured":"Ogilvie BW, Usuki E, Yerino P, Parkinson A (2020) In Vitro Approaches for Studying the Inhibition of Drug-Metabolizing Enzymes and Identifying the Drug-Metabolizing Enzymes Responsible for the Metabolism of Drugs (Reaction Phenotyping) with Emphasis on Cytochrome P450. Drug-Drug Interactions. Second Edi. Informa Healthcare, New York, pp 231\u2013358"},{"key":"1378_CR22","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1124\/dmd.110.033126","volume":"38","author":"OA Fahmi","year":"2010","unstructured":"Fahmi OA, Kish M, Boldt S, Scott Obach R (2010) Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 38:1605\u20131611. https:\/\/doi.org\/10.1124\/dmd.110.033126","journal-title":"Drug Metab Dispos"},{"key":"1378_CR23","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1124\/dmd.109.027029","volume":"37","author":"V Chu","year":"2009","unstructured":"Chu V, Einolf HJ, Evers R et al (2009) In vitro and in vivo induction of cytochrome P450: A survey of the current practices and recommendations: A Pharmaceutical Research and Manufacturers of America perspective. Drug Metab Dispos 37:1339\u20131354. https:\/\/doi.org\/10.1124\/dmd.109.027029","journal-title":"Drug Metab Dispos"},{"key":"1378_CR24","unstructured":"European Medicines Agency (2012) Investigation of drug interactions. https:\/\/www.ema.europa.eu\/en\/investigation-drug-interactions"},{"key":"1378_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1208\/s12248-009-9106-3","volume":"11","author":"L Zhang","year":"2009","unstructured":"Zhang L, Zhang Y, Zhao P, Huang SM (2009) Predicting drug-drug interactions: An FDA perspective. AAPS J 11:300\u2013306. https:\/\/doi.org\/10.1208\/s12248-009-9106-3","journal-title":"AAPS J"},{"key":"1378_CR26","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1124\/dmd.108.026252","volume":"37","author":"OA Fahmi","year":"2009","unstructured":"Fahmi OA, Hurst S, Plowchalk D et al (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: Predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658\u20131666. https:\/\/doi.org\/10.1124\/dmd.108.026252","journal-title":"Drug Metab Dispos"},{"key":"1378_CR27","unstructured":"US Food and Drug Administration (2020) Clinical Drug Interaction Studies \u2014 Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions"},{"key":"1378_CR28","doi-asserted-by":"publisher","first-page":"11936","DOI":"10.3390\/IJMS222111936","volume":"22","author":"D Vagiannis","year":"2021","unstructured":"Vagiannis D, Budagaga Y, Morell A et al (2021) Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo. Int J Mol Sci 22:11936. https:\/\/doi.org\/10.3390\/IJMS222111936","journal-title":"Int J Mol Sci"},{"key":"1378_CR29","unstructured":"US Food and Drug Administration (2020) Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01378-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01378-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01378-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:03:10Z","timestamp":1692792190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01378-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1378"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01378-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"assertion":[{"value":"8 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both clinical studies were conducted in accordance with the principles of the Declaration of Helsinki and the International Council on Harmonisation Good Clinical Practice guidelines. Both studies were conducted in Germany, and were approved by Ethik-Kommission der Bayerischen Landes\u00e4rztekammer (Ethics Committee, Bavarian Chamber of Physicians).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants before any study-related procedures were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"\u00d6zkan Yalkinoglu, Andreas Becker, Claudia Vetter, Christian L\u00fcpfert, Afrim Bytyqi, Rainer Strotmann, Axel Krebs-Brown, Angelika Bachmann and Dominique Perrin are (or were at the time of the studies) employees of the healthcare business of Merck KGaA, Darmstadt, Germany. J\u00fcrgen Heuer, Herlind Biedert and Stefan Hirt are employees of Nuvisan, Germany, who were contracted by the healthcare business Merck KGaA, Darmstadt, Germany, for support with the studies reported here.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}